Mechanism of immunomodulatory drug resistance and novel therapeutic strategies in multiple myeloma

References

• Van De Donk N, Pawlyn C, Yong KL. Multiple myeloma. The Lancet. 2021;397(10272):410–427.
   PubMed Web of Science ®Google Scholar
• Walker ZJ, Idler BM, Davis LN, et al. Exploiting protein translation dependence in multiple myeloma with omacetaxine-based therapy. Clin Cancer Res. 2021;27(3):819–830.
   PubMed Web of Science ®Google Scholar
• Kumar SK, Rajkumar V, Kyle RA, et al. Multiple myeloma. Nat Rev Dis Primers. 2017;3:17046.
   PubMed Web of Science ®Google Scholar
• Ramakrishnan VG, Miller KC, Macon EP, et al. Histone deacetylase inhibition in combination with MEK or Bcl-2 inhibition in multiple myeloma. Haematologica. 2019;104(10):2061–2074.
   PubMed Web of Science ®Google Scholar
• Shah V, Sherborne AL, Walker BA, et al. Prediction of outcome in newly diagnosed myeloma: A meta-analysis of the molecular profiles of 1905 trial patients. Leukemia. 2018;32(1):102–110.
   PubMed Web of Science ®Google Scholar
• Walker BA, Mavrommatis K, Wardell CP, et al. A high-risk, double-hit, group of newly diagnosed myeloma identified by genomic analysis. Leukemia. 2019;33(1):159–170.
   PubMed Web of Science ®Google Scholar
• Paiva B, Van Dongen JJ, Orfao A. New criteria for response assessment: role of minimal residual disease in multiple myeloma. Blood. 2015;125(20):3059–3068.
   PubMed Web of Science ®Google Scholar
• Flores-Montero J, Sanoja-Flores L, Paiva B, et al. Orfao A. Next Generation Flow for Highly Sensitive and Standardized Detection of Minimal Residual Disease in Multiple Myeloma. Leukemia. 2017;31(10):2094–2103.
   PubMed Web of Science ®Google Scholar
• Lahuerta JJ, Paiva B, Vidriales MB, et al. Depth of response in multiple myeloma: A pooled analysis of three PETHEMA/GEM clinical trials. J Clin Oncol. 2017;35(25):2900–2910.
   PubMed Web of Science ®Google Scholar
• Munshi NC, Avet-Loiseau H, Rawstron AC, et al. Association of minimal residual disease With superior survival outcomes in patients With multiple myeloma. JAMA Oncol. 2017;3(1):28–35.
   PubMed Web of Science ®Google Scholar
• Rawstron AC, Gregory WM, De Tute RM, et al. Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reduction. Blood. 2015;125(12):1932–1935.
   PubMed Web of Science ®Google Scholar
• Paiva B, Gutiérrez NC, Rosiñol L, et al. High-Risk Cytogenetics and Persistent Minimal Residual Disease by Multiparameter Flow Cytometry Predict Unsustained Complete Response After Autologous Stem Cell Transplantation in Multiple Myeloma. Blood. 2012;119(3):687–691.
   PubMed Web of Science ®Google Scholar
• Zuo X, Liu D. Progress in the application of minimal residual disease detection in multiple myeloma. J Hematop. 2021;14(2):97–107.
   Web of Science ®Google Scholar
• Pagnucco G, Cardinale G, Gervasi F. Targeting multiple myeloma cells and their bone marrow microenvironment. Ann N Y Acad Sci. 2004;1028:390–399.
   PubMed Web of Science ®Google Scholar
• Munshi NC, Anderson LD, Jr., Shah N, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384(8):705–716.
   PubMed Web of Science ®Google Scholar
• Yan Z, Cao J, Cheng H, et al. A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: A single-arm, phase 2 trial. Lancet Haematol. 2019;6(10):e521–e529.
   PubMed Web of Science ®Google Scholar
• Nerreter T, Letschert S, Gotz R, et al. Super-resolution microscopy reveals ultra-low CD19 expression on myeloma cells that triggers elimination by CD19 CAR-T. Nat Commun. 2019;10(1):3137.
   PubMedGoogle Scholar
• Yan L, Qu S, Shang J, et al. Sequential CD19 and BCMA-specific CAR T-cell treatment elicits sustained remission of relapsed and/or refractory myeloma. Cancer Med. 2021;10(2):563–574.
   PubMed Web of Science ®Google Scholar
• Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999;341(21):1565–1571.
   PubMed Web of Science ®Google Scholar
• D'amato RJ, Loughnan MS, Flynn E, et al. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A. 1994;91(9):4082–4085.
   PubMed Web of Science ®Google Scholar
• Ati ZE, Lamia R, Cherif J, et al. Thalidomide-induced bronchiolitis obliterans organizing pneumonia in a patient with multiple myeloma. Saudi J Kidney Dis Transpl. 2019;30(4):974–977.
   PubMed Web of Science ®Google Scholar
• Braga WM, Atanackovic D, Colleoni GW. The role of regulatory T cells and TH17 cells in multiple myeloma. Clin Dev Immunol. 2012;2012:293479.
   PubMed Web of Science ®Google Scholar
• Leleu X, Attal M, Arnulf B, et al. Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide–refractory multiple myeloma: intergroupe francophone du myélome 2009-02. Blood. 2013;121(11):1968–1975.
   PubMed Web of Science ®Google Scholar
• Lacy MQ, Hayman SR, Gertz MA, et al. Pomalidomide (CC4047) Plus low-dose dexamethasone as therapy for relapsed multiple myeloma. J Clin Oncol. 2009;27(30):5008–5014.
   PubMed Web of Science ®Google Scholar
• Lacy MQ, Allred JB, Gertz MA, et al. Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease. Blood. 2011;118(11):2970–2975.
   PubMed Web of Science ®Google Scholar
• Bjorklund CC, Kang J, Amatangelo M, et al. Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated crbn. Leukemia. 2020;34(4):1197–1201.
   PubMed Web of Science ®Google Scholar
• Matyskiela ME, Zhang W, Man HW, et al. A cereblon modulator (CC-220) with improved degradation of ikaros and aiolos. J Med Chem. 2018;61(2):535–542.
   PubMed Web of Science ®Google Scholar
• Ye Y, Gaudy A, Schafer P, et al. First-in-human, single- and multiple-ascending-dose studies in healthy subjects to assess pharmacokinetics, pharmacodynamics, and safety/tolerability of iberdomide, a novel cereblon E3 ligase modulator. Clin Pharmacol Drug Dev. 2021;10(5):471–485.
   PubMed Web of Science ®Google Scholar
• Fischer ES, Bohm K, Lydeard JR, et al. Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide. Nature. 2014;512(7512):49–53.
   PubMed Web of Science ®Google Scholar
• Ito T, Ando H, Suzuki T, et al. Identification of a primary target of thalidomide teratogenicity. Science. 2010;327(5971):1345–1350.
   PubMed Web of Science ®Google Scholar
• Lopez-Girona A, Mendy D, Ito T, et al. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia. 2012;26(11):2326–2335.
   PubMed Web of Science ®Google Scholar
• Diaz T, Rodriguez V, Lozano E, et al. The BET bromodomain inhibitor CPI203 improves lenalidomide and dexamethasone activity inin vitro and in vivo models of multiple myeloma by blockade of ikaros and MYC signaling. Haematologica. 2017;102(10):1776–1784.
   PubMed Web of Science ®Google Scholar
• Zhu YX, Shi CX, Bruins LA, et al. Identification of lenalidomide resistance pathways in myeloma and targeted resensitization using cereblon replacement, inhibition of STAT3 or targeting of IRF4. Blood Cancer J. 2019;9(2):19.
   PubMedGoogle Scholar
• Zhu YX, Braggio E, Shi CX, et al. Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood. 2011;118(18):4771–4779.
   PubMed Web of Science ®Google Scholar
• Kortum KM, Mai EK, Hanafiah NH, et al. Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes. Blood. 2016;128(9):1226–1233.
   PubMed Web of Science ®Google Scholar
• Broyl A, Kuiper R, Van Duin M, et al. High cereblon expression is associated with better survival in patients with newly diagnosed multiple myeloma treated with thalidomide maintenance. Blood. 2013;121(4):624–627.
   PubMed Web of Science ®Google Scholar
• Gooding S, Ansari-Pour N, Towfic F, et al. Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma. Blood. 2021;137(2):232–237.
   PubMed Web of Science ®Google Scholar
• Lu G, Weng S, Matyskiela M, et al. UBE2G1 governs the destruction of cereblon neomorphic substrates. Elife. 2018;7(e40958.
   Google Scholar
• Angers S, Li T, Yi X, et al. Molecular architecture and assembly of the DBB1-CuL4A ubiquitin ligase machinery. Nature. 2006;443(7111):590–593.
   PubMed Web of Science ®Google Scholar
• Barankiewicz J, Szumera-Cieckiewicz A, Salomon-Perzynski A, et al. The CRBN, The CRBN, CUL4A and DDB1 expression predicts the response to immunomodulatory drugs and survival of multiple myeloma patients. J Clin Med. 2021;10(12):2683.
   PubMed Web of Science ®Google Scholar
• Heizmann B, Kastner P, Chan S. The ikaros family in lymphocyte development. Curr Opin Immunol. 2018;51:14–23.
   PubMed Web of Science ®Google Scholar
• Zhu YX, Braggio E, Shi CX, et al. Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma. Blood. 2014;124(4):536–545.
   PubMed Web of Science ®Google Scholar
• Kronke J, Kuchenbauer F, Kull M, et al. IKZF1 expression is a prognostic marker in newly diagnosed standard-risk multiple myeloma treated with lenalidomide and intensive chemotherapy: A study of the German myeloma study group (DSMM). Leukemia. 2017;31(6):1363–1367.
   PubMed Web of Science ®Google Scholar
• Nguyen TV, Lee JE, Sweredoski MJ, et al. Glutamine triggers acetylation-dependent degradation of glutamine synthetase via the thalidomide receptor cereblon. Mol Cell. 2016;61(6):809–820.
   PubMed Web of Science ®Google Scholar
• Hensley CT, Wasti AT, Deberardinis RJ. Glutamine and cancer: cell biology, physiology, and clinical opportunities. J Clin Invest. 2013;123(9):3678–3684.
   PubMed Web of Science ®Google Scholar
• Nguyen TV, Li J, Lu CJ, et al. P97/VCP promotes degradation of CRBN substrate glutamine synthetase and neosubstrates. Proc Natl Acad Sci U S A. 2017;114(14):3565–3571.
   PubMed Web of Science ®Google Scholar
• Nguyen TV. USP15 antagonizes CRL4CRBN-mediated ubiquitylation of glutamine synthetase and neosubstrates. Proc Natl Acad Sci U S A. 2021;118(40):e2111391118.
   PubMed Web of Science ®Google Scholar
• An J, Ponthier CM, Sack R, et al. pSILAC mass spectrometry reveals ZFP91 as IMiD-dependent substrate of the CRL4CRBN ubiquitin ligase. Nat Commun. 2017;8(15398).
   Google Scholar
• Krönke J, Udeshi ND, Narla A, et al. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science. 2014: 343(6168): 301-305.
   PubMed Web of Science ®Google Scholar
• Quintana FJ, Jin H, Burns EJ, et al. Aiolos promotes TH17 differentiation by directly silencing IL2 expression. Nat Immunol 2012;13(8):770–777.
   PubMed Web of Science ®Google Scholar
• Hideshima T, Ogiya D, Liu J, et al. Immunomodulatory drugs activate NK cells via both Zap-70 and cereblon-dependent pathways. Leukemia. 2021;35(1):177–188.
   PubMed Web of Science ®Google Scholar
• Fedele PL, Liao Y, Gong JN, et al. The transcription factor IRF4 represses proapoptotic BMF and BIM to licence multiple myeloma survival. Leukemia. 2021;35(7):2114–2118.
   PubMed Web of Science ®Google Scholar
• Low MSY, Brodie EJ, Fedele PL, et al. IRF4 activity is required in established plasma cells to regulate gene transcription and mitochondrial homeostasis. Cell Rep. 2019;29(9):2634–2645.e5 e2635.
   PubMed Web of Science ®Google Scholar
• Conery AR, Centore RC, Neiss A, et al. Bromodomain inhibition of the transcriptional coactivators CBP/EP300 as a therapeutic strategy to target the IRF4 network in multiple myeloma. Elife. 2016;5(e19432.
   Google Scholar
• Li S, Pal R, Monaghan SA, et al. IMiD immunomodulatory compounds block C/EBP{beta} translation through eIF4E down-regulation resulting in inhibition of MM. Blood. 2011;117(19):5157–5165.
   PubMed Web of Science ®Google Scholar
• Xie Z, Bi C, Chooi JY, et al. MMSET regulates expression of IRF4 in t(4;14) myeloma and its silencing potentiates the effect of bortezomib. Leukemia. 2015;29(12):2347–2354.
   PubMed Web of Science ®Google Scholar
• Lu G, Middleton RE, Sun H, et al. The myeloma drug lenalidomide promotes the cereblon-dependent destruction of ikaros proteins. Science. 2014;343(6168):305–309.
   PubMed Web of Science ®Google Scholar
• Ochiai K, Yamaoka M, Swaminathan A, et al. Chromatin protein PC4 orchestrates B cell differentiation by collaborating with ikaros and IRF4. Cell Rep. 2020;33(12):108517.
   PubMed Web of Science ®Google Scholar
• Bai H, Wu S, Wang R, et al. Bone marrow IRF4 level in multiple myeloma: An indicator of peripheral blood TH17 and disease. Oncotarget. 2017;8(49):85392–85400.
   PubMedGoogle Scholar
• Lamy L, Ngo VN, Emre NC, et al. Control of Autophagic Cell Death by Caspase-10 in multiple myeloma. Cancer Cell. 2013;23(4):435–449.
   PubMed Web of Science ®Google Scholar
• Morelli E, Leone E, Cantafio ME, et al. Selective targeting of IRF4 by synthetic microRNA-125b-5p mimics induces anti-multiple myeloma activity in vitro and in vivo. Leukemia. 2015;29(11):2173–2183.
   PubMed Web of Science ®Google Scholar
• Shaffer AL, Emre NC, Lamy L, et al. IRF4 addiction in multiple myeloma. Nature. 2008;454(7201):226–231.
   PubMed Web of Science ®Google Scholar
• Affer M, Chesi M, Chen WG, et al. Promiscuous MYC locus rearrangements hijack enhancers but mostly super-enhancers to dysregulate MYC expression in multiple myeloma. Leukemia. 2014;28(8):1725–1735.
   PubMed Web of Science ®Google Scholar
• Yamamoto J, Suwa T, Murase Y, et al. ARID2 is a pomalidomide-dependent CRL4CRBN substrate in multiple myeloma cells. Nat Chem Biol. 2020;16(11):1208–1217.
   PubMed Web of Science ®Google Scholar
• Kuehl WM, Bergsagel PL. MYC addiction: A potential therapeutic target in MM. Blood. 2012;120(12):2351–2352.
   PubMed Web of Science ®Google Scholar
• Gandhi AK, Mendy D, Waldman M, et al. Measuring cereblon as a biomarker of response or resistance to lenalidomide and pomalidomide requires use of standardized reagents and understanding of gene complexity. Br J Haematol. 2014;164(2):233–244.
   PubMed Web of Science ®Google Scholar
• Spriano F, Gaudio E, Cascione L, et al. Antitumor activity of the dual BET and CBP/EP300 inhibitor NEO2734. Blood Adv. 2020;4(17):4124–4135.
   PubMed Web of Science ®Google Scholar
• Egger G, Liang G, Aparicio A, et al. Epigenetics in human disease and prospects for epigenetic therapy. Nature. 2004;429(6990):457–463.
   PubMed Web of Science ®Google Scholar
• Ntranos A, Casaccia P. Bromodomains: translating the words of lysine acetylation into myelin injury and repair. Neurosci Lett. 2016;625:4–10.
   PubMed Web of Science ®Google Scholar
• Perez-Salvia M, Esteller M. Bromodomain inhibitors and cancer therapy: from structures to applications. Epigenetics. 2017;12(5):323–339.
   PubMed Web of Science ®Google Scholar
• Grossman SR. P300/CBP/p53 interaction and regulation of the p53 response. Eur J Biochem. 2001;268(10):2773–2778.
   PubMedGoogle Scholar
• Munawar U, Roth M, Barrio S, et al. Assessment of TP53 lesions for p53 system functionality and drug resistance in multiple myeloma using an isogenic cell line model. Sci Rep. 2019;9(1):18062.
   PubMedGoogle Scholar
• Hideshima T, Cottini F, Nozawa Y, et al. P53-related protein kinase confers poor prognosis and represents a novel therapeutic target in multiple myeloma. Blood. 2017;129(10):1308–1319.
   PubMed Web of Science ®Google Scholar
• Escoubet-Lozach L, Lin IL, Jensen-Pergakes K, et al. Pomalidomide and lenalidomide induce p21WAF-1 expression in both lymphoma and multiple myeloma through a LSD1-mediated epigenetic mechanism. Cancer Res 2009;69(18):7347–7356.
   PubMed Web of Science ®Google Scholar
• Hideshima T, Chauhan D, Shima Y, et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood. 2000;96(9):2943–2950.
   PubMed Web of Science ®Google Scholar
• Haertle L, Barrio S, Munawar U, et al. Cereblon enhancer methylation and IMiD resistance in multiple myeloma. Blood. 2021;138(18):1721–1726.
   PubMed Web of Science ®Google Scholar
• Loven J, Hoke HA, Lin CY, et al. Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell. 2013;153(2):320–334.
   PubMed Web of Science ®Google Scholar
• Doroshow DB, Eder JP, Lorusso PM. BET inhibitors: A novel epigenetic approach. Ann Oncol. 2017;28(8):1776–1787.
   PubMed Web of Science ®Google Scholar
• Holien T, Vatsveen TK, Hella H, et al. Addiction to c-MYC in multiple myeloma. Blood. 2012;120(12):2450–2453.
   PubMed Web of Science ®Google Scholar
• Zhang X, Lee HC, Shirazi F, et al. Protein targeting chimeric molecules specific for bromodomain and extra-terminal motif family proteins are active against pre-clinical models of multiple myeloma. Leukemia. 2018;32(10):2224–2239.
   PubMed Web of Science ®Google Scholar
• Bjorklund CC, Ma W, Wang ZQ, et al. Evidence of a role for activation of Wnt/β-catenin signaling in the resistance of plasma cells to lenalidomide. J Biol Chem. 2011;286(13):11009–11020.
   PubMed Web of Science ®Google Scholar
• Butrym A, Rybka J, Lacina P, et al. Polymorphisms within beta-catenin encoding gene affect multiple myeloma development and treatment. Leuk Res. 2015;39(12):1462–1466.
   PubMed Web of Science ®Google Scholar
• Tang S, Cheng B, Zhe N, et al. Histone deacetylase inhibitor BG45-mediated HO-1 expression induces apoptosis of multiple myeloma cells by the JAK2/STAT3 pathway. Anticancer Drugs. 2018;29(1):61–74.
   PubMed Web of Science ®Google Scholar
• Tenshin H, Teramachi J, Oda A, et al. TAK1 inhibition subverts the osteoclastogenic action of TRAIL while potentiating its antimyeloma effects. Blood Adv. 2017;1(24):2124–2137.
   PubMed Web of Science ®Google Scholar
• Haland E, Moen IN, Veidal E, et al. TAK1-inhibitors are cytotoxic for multiple myeloma cells alone and in combination with melphalan. Oncotarget. 2021;12(21):2158–2168.
   PubMedGoogle Scholar
• Paiva B, Corchete LA, Vidriales MB, et al. Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: a new model to understand chemoresistance. Blood. 2016;127(15):1896–1906.
   PubMed Web of Science ®Google Scholar
• Bjorklund CC, Baladandayuthapani V, Lin HY, et al. Evidence of a role for CD44 and cell adhesion in mediating resistance to lenalidomide in multiple myeloma: therapeutic implications. Leukemia. 2014;28(2):373–383.
   PubMed Web of Science ®Google Scholar
• Yin L, Tagde A, Gali R, et al. MUC1-C is a target in lenalidomide resistant multiple myeloma. Br J Haematol. 2017;178(6):914–926.
   PubMed Web of Science ®Google Scholar
• Sebastian S, Zhu YX, Braggio E, et al. Multiple myeloma cells’ capacity to decompose H2O2 determines lenalidomide sensitivity. Blood. 2017;129(8):991–1007.
   PubMed Web of Science ®Google Scholar
• Barrera LN, Rushworth SA, Bowles KM, et al. Bortezomib induces heme oxygenase-1 expression in multiple myeloma. Cell Cycle. 2012;11(12):2248–2252.
   PubMed Web of Science ®Google Scholar
• Wu W, Ma D, Wang P, et al. Potential crosstalk of the interleukin-6-heme oxygenase-1-dependent mechanism involved in resistance to lenalidomide in multiple myeloma cells. FEBS J. 2016;283(5):834–849.
   PubMed Web of Science ®Google Scholar
• Siu KT, Ramachandran J, Yee AJ, et al. Preclinical Activity of CPI-0610, a novel small-molecule bromodomain and extra-terminal protein inhibitor in the therapy of multiple myeloma. Leukemia. 2017;31(8):1760–1769.
   PubMed Web of Science ®Google Scholar
• Abruzzese MP, Bilotta MT, Fionda C, et al. Inhibition of bromodomain and extra-terminal (BET) proteins increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: role of cMYC-IRF4-miR-125b interplay. J Hematol Oncol. 2016;9(1):134.
   PubMedGoogle Scholar
• Amorim S, Stathis A, Gleeson M, et al. Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: A dose-escalation, open-label, pharmacokinetic, phase 1 study. Lancet Haematol. 2016;3(4):e196–e204.
   PubMed Web of Science ®Google Scholar
• Delmore JE, Issa GC, Lemieux ME, et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell. 2011;146(6):904–917.
   PubMed Web of Science ®Google Scholar
• Filippakopoulos P, Qi J, Picaud S, et al. Selective inhibition of BET bromodomains. Nature. 2010;468(7327):1067–1073.
   PubMed Web of Science ®Google Scholar
• Shu S, Lin CY, He HH, et al. Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer. Nature. 2016;529(7586):413–417.
   PubMed Web of Science ®Google Scholar
• Rathert P, Roth M, Neumann T, et al. Transcriptional plasticity promotes primary and acquired resistance to BET inhibition. Nature. 2015;525(7570):543–547.
   PubMed Web of Science ®Google Scholar
• Van Gils N, Martiañez Canales T, Vermue E, et al. The novel oral BET-CBP/p300 dual inhibitor NEO2734 is highly effective in eradicating acute myeloid leukemia blasts and stem/progenitor cells. Hemasphere. 2021;5(8):e610.
   PubMed Web of Science ®Google Scholar
• Ryan KR, Giles F, Morgan GJ. Targeting both BET and CBP/EP300 proteins with the novel dual inhibitors NEO2734 and NEO1132 leads to anti-tumor activity in multiple myeloma. Eur J Haematol. 2021;106(1):90–99.
   PubMed Web of Science ®Google Scholar
• Won HR, Lee DH, Yeon SK, et al. HDAC6-selective inhibitor synergistically enhances the anticancer activity of immunomodulatory drugs in multiple myeloma. Int J Oncol. 2019;55(2):499–512.
   PubMed Web of Science ®Google Scholar
• Niesvizky R, Ely S, Mark T, et al. Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma. Cancer. 2011;117(2):336–342.
   PubMed Web of Science ®Google Scholar
• Ocio EM, Fernandez-Lazaro D, San-Segundo L, et al. In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone. Leukemia. 2015;29(3):705–714.
   PubMed Web of Science ®Google Scholar
• Holkova B, Zingone A, Kmieciak M, et al. A phase II trial of AZD6244 (selumetinib. ARRY; 142886), an oral MEK1/2 inhibitor, in relapsed/refractory multiple myeloma. Clin Cancer Res. 2016;22(5):1067–1075.
   PubMed Web of Science ®Google Scholar
• Morales AA, Gutman D, Lee KP, et al. BH3-only proteins noxa, Bmf, and Bim are necessary for arsenic trioxide-induced cell death in myeloma. Blood. 2008;111(10):5152–5162.
   PubMed Web of Science ®Google Scholar
• Jian Y, Gao W, Geng C, et al. Arsenic trioxide potentiates sensitivity of multiple myeloma cells to lenalidomide by upregulating cereblon expression levels. Oncol Lett. 2017;14(3):3243–3248.
   PubMed Web of Science ®Google Scholar
• Wen J, Cheng HY, Feng Y, et al. P38 MAPK inhibition enhancing ATO-induced cytotoxicity against multiple myeloma cells. Br J Haematol. 2008;140(2):169–180.
   PubMed Web of Science ®Google Scholar
• Buglio D, Palakurthi S, Byth K, et al. Essential role of TAK1 in regulating mantle cell lymphoma survival. Blood. 2012;120(2):347–355.
   PubMed Web of Science ®Google Scholar
• Teramachi J, Tenshin H, Hiasa M, et al. TAK1 is a pivotal therapeutic target for tumor progression and bone destruction in myeloma. Haematologica. 2021;106(5):1401–1413.
   PubMed Web of Science ®Google Scholar
• Navas TA, Nguyen AN, Hideshima T, et al. Inhibition of p38alpha MAPK enhances proteasome inhibitor-induced apoptosis of myeloma cells by modulating Hsp27, Bcl-X(L). Mcl; 1, and p53 levels in vitro and inhibits tumor growth in vivo. Leukemia. 2006;20(6):1017–1027.
   PubMed Web of Science ®Google Scholar
• Chen Y-H, Lavelle D, Desimone J, et al. Growth inhibition of a human myeloma cell line by All-transRetinoic acid Is Not mediated through downregulation of interleukin-6 receptors but through upregulation of p21WAF1. Blood. 1999;94(1):251–259.
   PubMed Web of Science ®Google Scholar
• Liu Z, Li T, Jiang K, et al. Induction of chemoresistance by all-trans retinoic acid via a noncanonical signaling in multiple myeloma cells. PLoS One. 2014;9(1):e85571.
   PubMed Web of Science ®Google Scholar
• Wang S, Tricot G, Shi L, et al. RARα2 expression is associated with disease progression and plays a crucial role in efficacy of ATRA treatment in myeloma. Blood. 2009;114(3):600–607.
   PubMed Web of Science ®Google Scholar
• Lou YJ, Qian WB, Jin J. Homoharringtonine induces apoptosis and growth arrest in human myeloma cells. Leuk Lymphoma. 2007;48(7):1400–1406.
   PubMed Web of Science ®Google Scholar
• Li M, Shi F, Fei X, et al. PEGylated long-circulating liposomes deliver homoharringtonine to suppress multiple myeloma cancer stem cells. Exp Biol Med (Maywood). 2017;242(9):996–1004.
   PubMed Web of Science ®Google Scholar
• Li M, Fei X, Shi F, et al. Homoharringtonine delivered by high proportion PEG of long- circulating liposomes inhibits RPMI8226 multiple myeloma cells in vitro and in vivo. Am J Transl Res. 2016;8(3):1355–1368.
   PubMed Web of Science ®Google Scholar
• Damlaj M, Lipton JH, Assouline SE. A safety evaluation of omacetaxine mepesuccinate for the treatment of chronic myeloid leukemia. Expert Opin Drug Saf. 2016;15(9):1279–1286.
   PubMed Web of Science ®Google Scholar
• Gurel G, Blaha G, Moore PB, et al. Determines the species specificity of the a-site cleft antibiotics: The structures of tiamulin, homoharringtonine, and bruceantin bound to the ribosome. J Mol Biol. 2504;2009:389(1): 146-156.
   Google Scholar
• Tang R, Faussat AM, Majdak P, et al. Semisynthetic homoharringtonine induces apoptosis via inhibition of protein synthesis and triggers rapid myeloid cell leukemia-1 down-regulation in myeloid leukemia cells. Mol Cancer Ther. 2006;5(3):723–731.
   PubMed Web of Science ®Google Scholar
• Allan EK, Holyoake TL, Craig AR, et al. Omacetaxine may have a role in chronic myeloid leukaemia eradication through downregulation of Mcl-1 and induction of apoptosis in stem/progenitor cells. Leukemia. 2011;25(6):985–994.
   PubMed Web of Science ®Google Scholar
• Chen R, Guo L, Chen Y, et al. Homoharringtonine reduced Mcl-1 expression and induced apoptosis in chronic lymphocytic leukemia. Blood. 2011;117(1):156–164.
   PubMed Web of Science ®Google Scholar
• Papatzimas JW, Gorobets E, Maity R, et al. From inhibition to degradation: targeting the antiapoptotic protein myeloid cell leukemia 1 (Mcl1). J Med Chem. 2019;62(11):5522–5540.
   PubMed Web of Science ®Google Scholar
• Buckley DL, Crews CM. Small-molecule control of intracellular protein levels through modulation of the ubiquitin proteasome system. Angew Chem Int Ed Engl. 2014;53(9):2312–2330.
   PubMed Web of Science ®Google Scholar
• Sun B, Fiskus W, Qian Y, et al. BET protein proteolysis targeting chimera (PROTAC) exerts potent lethal activity against mantle cell lymphoma cells. Leukemia. 2018;32(2):343–352.
   PubMed Web of Science ®Google Scholar
• Lim SL, Damnernsawad A, Shyamsunder P, et al. Proteolysis targeting chimeric molecules as therapy for multiple myeloma: efficacy, biomarker and drug combinations. Haematologica. 2019;104(6):1209–1220.
   PubMed Web of Science ®Google Scholar
• Roy MJ, Winkler S, Hughes SJ, et al. SPR-measured dissociation kinetics of PROTAC ternary complexes influence target degradation rate. ACS Chem Biol 2019;14(3):361–368.
   PubMed Web of Science ®Google Scholar
• Bondeson DP, Mares A, Smith IE, et al. Catalytic in vivo protein knockdown by small-molecule PROTACs. Nat Chem Biol. 2015;11(8):611–617.
   PubMed Web of Science ®Google Scholar
• Gupta VA, Matulis SM, Conage-Pough JE, et al. Bone marrow microenvironment-derived signals induce Mcl-1 dependence in multiple myeloma. Blood. 2017;129(14):1969–1979.
   PubMed Web of Science ®Google Scholar